Defiance ETFs launches Junior Biotechnology ETF

Defiance ETFs has launched the Defiance Nasdaq Junior Biotechnology ETF (IBBJ), which tracks the Nasdaq Junior Biotechnology Index, offering investors exposure to small and mid-cap “junior” companies with a market capitalisation below USD5 billion.

“At Defiance, we believe in providing the next generation of investors with targeted exposure to disruptive themes. IBBJ does just that, offering exposure to the junior disruptors in the biotech space, and allowing investors to express either a short- or long-term view,” says Matthew Bielski, Chief Executive Officer at Defiance ETFs.

Cameron Lilja, Vice President and Head of Index Research and Development for Nasdaq Global Indexes, says: “Nasdaq works with a global community of healthcare leaders, including 98 per cent of US listed biotech companies,” said “The Nasdaq Junior Biotechnology Index allows investors to track the performance of small and mid-cap biotechnology companies, and our work with Defiance ETFs empowers investors with access to this important centre of innovation.”